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Two series of antigenic variants of influenza  virus type A, PR8 strain,  have 
been characterized  serologically  (1,  2).  In  the  original  series,  seven variants 
derived in succession  in mice immunized  with  the  homologous  virus showed 
a progressive deviation from the parent PR8-S virus when tested with PR8-S 
antiserum. However, all variants continued to produce some antibody reacting 
with PRS-S virus. The fifth and sixth variants produced antibody with signif- 
icantly less cross-reaction to PR8-S virus, but antiserum of the seventh variant 
showed somewhat higher  levels of PR8-S antibody resembling in this respect 
the antisera of the first four variants.  By cross-absorption tests, it was shown 
that  the  variants  contained  new  antigenic  components  which  were  shared 
in different amounts. 
The second series  of four variants  were derived from the  third  variant  of 
the  original  series  by passage in mice immunized  with  PRS-S virus.  Subse- 
quent  variants  were developed in  mice  given  polyvalent vaccine  composed 
of PR8-S virus and the preceding variant.  In this series the first variant  was 
not serologically  different from its parent. 
However, the three subsequent variants  showed marked serological  devia- 
tion from the variants of the original line. They reacted only slightly with PRS- 
antiserum and provoked only small  amounts of antibody which reacted with 
the PRS-S virus. The results of cross-protection tests in mice also reflect  the 
marked antigenic differences noted in the H.I. and neutralization  tests. These 
along  with  the  results  of  experiments  to  show  virulence,  antigenicity  and 
immunogenicity of some of the variants of both series compared to the original 
PRS-S virus will be given in this report. 
* These  investigations were  conducted  under  the  sponsorship  of  the  Commission on 
Influenza, Armed Forces Epidemiological Board and were  supported (in part)  by the Office 
of the Surgeon General, Department of the Army; and  (in part)  by the Seymour Coman 
Fellowship Fund of  the  University of  Chicago. 
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Materials  and  Methods 
The methods employed in the production  of the two sedes of variants of PR8-S virus 
and  the serological  procedures used to characterize them serologically have been described 
in previous reports  (1, 2).  The details of the tests for demonstrating comparative virulence 
antigenicity, immunogenicity, and cross-protection will be given in the appropriate sections 
under Results. 
RESULTS 
Pathogenicity  (Virulence)  of  the  Variant  Viruses  for  Mice  and  Chick 
Embryos.--It  was  anticipated  that  the  method  employed  in  the  production 
TABLE I 
Pathogenicity of PRS-S and Its Variant Viruses  for Chick Embryos and Mice 
Viruses 
First series 
PR8-S 
As22N6 
Ba25N20 
Cbl7N13 
Dc26N4 
Fdl9N5 
Gf33N8 
Hg33N5 
Second series 
Cbl7N13 
D/s45N5 
Fd/s20N12 
Gf/s25N5 
Hg/s30N5 
Log titers 
EID6o 
8.3 
8.6 
8.5 
8.6 
8.0 
7.6 
8.4 
8.6 
8.6 
7.6 
8.5 
8.4 
8.5 
LD60 
6.5 
7.2 
6.8 
7.5 
6.4 
6.0 
6.8 
6.5 
7.5 
6.2 
6.8 
7.0 
6.5 
EIDs0 
LD~a 
1.8 
1.4 
1.7 
1.1 
1.6 
1.6 
1.6 
2.1 
i.I 
1.4 
1.7 
1.4 
2.0 
of the variants would not favor the selection of non-virulent strains.  However, 
while there was no obvious evidence that  the PR8-S variants  differed in their 
ability  to  infect  and  kill  mice  and  eggs,  tests  were carried  out to  determine 
their  comparable  pathogenicity. 
Individual mouse lung virus suspensions  with PR8-S or its variant were prepared. Groups 
of five normal  mice each weighing 19  to 22  gin.  were inoculated  intranasally  under  light 
ether anesthesia with 0.05 ml. of a  10  4  dilution of each lung-virus suspension.  At 48 hours 
after inoculation the mice of each group were killed, their lungs pooled, and ground in sterile 
sand. Ten per cent suspensions  of stock viruses were prepared. Each lot of sterile virus was 
then divided into small aliquots,  quickly frozen, and  stored  at  --50°C.  EID60 and  LDs0 
titers were then determined on each lung virus suspension.  Five 10 day fertile eggs and five 
mice were inoculated respectively with 0.2  nil. intraaUantoieally and 0.05  ml. intranasally 
with each tenfold dilution of a  given virus suspension. CLAYTON  G. LOOSLI,  DOROTHY  HAMILE~ AND PAUL GERBER  859 
The results are shown in Table I. As can be seen the EID~o and LD60 titers 
of the original PR8-S virus and the variant viruses of both series were essen- 
tially the same. This is also seen on inspection of ratios of the EIDs0 and LD60 
titers.  Furthermore,  examination of  the  time  of  death  of  mice  inoculated 
intranasally with tenfold dilutions of PR8-S or variant viruses failed to show 
any significant difference. 
Antigenic Potency  of PRS-S and Variant Viruses.--During  the development 
of the two series of PR8-S variants it was noted that while all variants appeared 
to  retain  the  same  degree  of  virulence or  pathogenicity for  mice and  chick 
TABLE II 
Antigenic Potency of PR8-S Virus and Its Variants 
Virus 
First series 
PR8-S 
As22N6 
Ba25N2 
CblTN24 
Dc26N7 
Fdl9N5 
Gf33N8 
Hg33N5 
Second series 
CbI7N24 
D/s45N2 
Fd/s20N2 
Gf/s25N5 
Hg/s30N5 
Homologous H.I. titers  with HA 
units/dose of vaccine 
8 HA  128 HA 
128  512 
48  384 
32  128 
60  120 
64  192 
8  32 
16  48 
12  64 
60 
8 
<8 
<8 
<8 
120 
32 
16 
8 
12 
Recovered mice 
44O 
64 
96 
96 
64 
45 
8 
48 
96 
64 
22 
8 
8 
embryos there was a  progressive loss in the ability of each successive variant 
to produce homologous antibody. In order to evaluate on a  comparative basis 
the ability of the different variants to produce antibody the following experi- 
ments were carried out. 
Monovalent  formalin-inactivated  allantoic  fluid vaccines, one with  128  HA  units and 
the other with 8 HA units of virus, were prepared with the PR8-S virus and each variant. 
A group of five mice each weighing 19 to 22 gin. was given intraperitoneally 0.5 ml. each of 
the high titer vaccine and another group of mice the same amount of the low titer vaccine. 
Fourteen days after inoculation the five mice from each group were bled from the axillary 
vein. The blood was pooled and serum H.I. and in ovo neutralizing antibody titers for ho- 
mologous antibody were determined. Also to demonstrate  the loss of antigenic potency  of 
the variant viruses, sera from mice surviving the virulence tests and showing pulmonary 
lesions were tested  for homologous antibody. The results are  shown in Table II. 860  ANTIGENIC VARIANTS OF INFLUENZA  A  VIRUS. V 
It can be seen that the PR8-S virus produced the greatest antibody response 
following both vaccination and infection. Among the variant viruses the anti- 
body response progressively decreased to the point where no antibody could 
be detected in the sera of mice vaccinated with 8 HA units of the final three 
variants of the second series, and only small amounts following vaccination 
with 128 HA units or after infection. In ova neutralizing  antibody fiters, not 
Homologous 
Challenge 
Dose, LDsoS 
Intronosolly 
310 
3,100 
31,000 
310,000 
I.P Vaccine 
Dose In 
HA 
Units 
I0 
80 
640 
lO 
80 
640 
I0 
80 
640 
I0 
80 
640 
PRS-S Vaccine 
Challenged  With PRS-S 
HI  HT 
Titer  Titer 
Before  Results  After 
64  ~  384 
384  768 
512  256 
64  ~  512 
384  768 
512  512 
64  1  D24 
3B"  1  768 
512  768 
64 
384 
512 
192 
1536 
1024 
Fd/S Vaccine 
Challenged With. Fd/S 
HI  HI 
Titer  Titer 
Before  Results  After 
<8 
12  96 
96  192 
<8  256 
2.56 
12B 
<8 
12 
96 
384 
512 
192 
<8 
12 
96  ~1  256 
Legend :  1  Died  []  Survived,Lesions  in Lung  []  Survived, No Lesions 
FIG.  1.  Comparison  of  the immunogenicity of  PR8-S  virus and  Fd/s  variant virus in 
mice. 
shown  in  Table  II,  also  showed  a  similar  decrease  with  each  succeeding 
variant. 
Immunogenidty  of Low and High Potency  Antigens.--To  demonstrate the 
effect of different antigenic responses upon resistance to homologous challenge 
with equally pathogenic viruses,  Fd/s variant, a poor antigen, was compared 
with PR8-S,  a good antigen. 
A  first egg passage  aUantoic fluid harvest vaccine was prepared  with  each  strain and 
inactivated with formalin. From each vaccine three lots each respectively containing 640, 
80, and 10 HA units were prepared.  Groups of 25 mice were then inoculated with a  given 
lot,  each  mouse  receiving 0.5  ml.  intraperitoneally. Fourteen days  after  vaccination each CLAYTON G.  LOOSLI,  DOROTHY i~i~,  AND  PAUL  GERBER  861 
group  of mice receiving a  lot of vaccine were divided into groups of five. Five mice (one 
group) were bled and the sera pooled for antibody determination. A group of five mice re- 
ceiving each lot of vaccine and a  control group of unvaccinated mice were then inoculated 
intranasally  with increasing amounts  (tenfold  increases)  of mouse  lung passage  influenza 
virus having an LDs0 titer of 10  6-s. The mice were then observed for death or survival over 
TABLE III 
Cross-Protectlon  Tests with PR8-S and  Variants Fd, Gf, and ttg of the Original  Line 
Experiment 
No. 
Challenge virus 
100 LADso 
PR8-S 
Fdl9 
PR8-S 
Gf33 
PR8-S 
Hg33 
Vaceme 
Control 
PR8-S 
Fd19 
Control 
PR8-S 
Fdl9 
J 
!  Control 
PR8-S 
Gf33 
Control 
PR8-S 
Gf33 
Control 
PR8-S 
Hg33 
Control 
PR8-S 
Hg33 
H.I. titer*  Results of challenge 
Dead  Lesions  Lung titer¢  PRS-S  Variant  Total  " Total  EID60 
--  --  20/20  20/20  9.0 
250  <16  0/20  1/20  <1.0 
64  192  0/20  0/20  <1.0 
--  --  20/20  20/20  9.2 
256  <16  7/19  18/19  7.9 
64  192  0/20  0/20  <1.0 
290 
<8 
290 
<8 
63O 
49 
630 
I  49 
--  10/10  10/10  9.5 
<8  0/I0  1/10  <1.0 
9t  0/10  0/10  7.0 
--  10/10  10/10  9.0 
<8  2/10  10/10  7.3 
91  0/10  0/10  <1.0 
--  10/10  10/10  9.3 
<8  0/10  0/10  <1.0 
178  0/10  1/10  6.0 
<8 
178 
10/10 
1/lO 
O/lO 
10/10  8.7 
5/10  6.7 
0/10  <1.0 
* Geometric mean titers of 5 mice 12 to 14 days after last 
titers in bold type. 
:~ Log EIDs0 48 hours after challenge. 
dose of vaccine. Homologous 
a  14  day period.  Those dying were examined  for pulmonary  consolidation and  those sur- 
viving were  sacrificed  at  14  days  and  examined  for lung lesions. 
The results are shown in Fig. 1. As can be seen, the three PR8-S virus vac- 
cines provoked considerably more antibody than did the Fd/s variant vaccines 
of comparable strength. When the two vaccine groups of mice were challenged 
with  the  same  amounts  of respective homologous virus,  in  both  groups  as 
would be expected, the greatest number of deaths occurred in the group with 
the  lowest  antibody  titers.  However,  more  Fd/s-vaccinated  mice  died  or 862  ANTIGENIC  VARIANTS  OF  INFLUENZA  A  VIRUS.  V 
showed lesions in all four challenge groups than did PR8-S vaccinated animals. 
Fd/s-vaccinated  mice  which  survived  challenge  showed  proportionally  a 
greater boost in antibody titer than was found in the surviving PR8-S mice. 
Cross-Protection  Tests.--Cross-challenge  protection  tests  were  carried  out 
as follows. 
Mice of the same age and weight were employed.  Three groups of mice were employed 
in each cross-challenge test.  One  served as  controls,  one was  vaccinated intraperitoneally 
with the PR8-S  virus vaccine and  the other with a  given variant vaccine. The group  re- 
ceiving the PR8-S vaccine were given two 0.5 ml. doses at 5 to 7 day intervals while those 
receiving the variant vaccines were given three 0.5 ml. doses in an attempt to produce corn- 
TABLE  IV 
Comparison of Growth of Cb17, Ds45 and PR8-S in the Lungs of Mice Recovered  from 
Infection with PRS-S 
Virus strain  Mouse LDs0 doses inoculated  intranasally  Lung titer 48 hours EIDl0 
PR8-S 
Cb17 
Ds45 
10,000  <1.0 
1,000  <1.0 
10,000 
1,000 
100 
10,000 
1,000 
100 
6.5 
6.5 
4.2 
6.5 
6.0 
6.3 
parable  antibody levels. The  viruses in the  Fd/s,  Gf/s,  and  Hg/s  vaccines were  concen- 
trated  tenfold  by  high  speed  centrifugation in  order  to  produce  reasonably  comparable 
antibody titers to those elicited by the diluted PR8-S vaccines, Sufficient mice were vacci- 
nated with each vaccine so that the prechallenge antibody titers would  be determined on 
the pooled blood of five mice, another three were sacrificed at 48 hours after challenge to 
determine lung virus titers and at least ten mice used to determine deaths or survival rates. 
The challenge tests were carried out from  10 to  14 days after the last vaccine inocula- 
tion. In the tests all challenge doses of virus were given by aerosol with one exception. The 
amount was  100  lethal ~ir-borne dosess0  (LADs0)  given in a  closed chamber. The LADs0 
of each virus was previously determined by titration of tenfold dilutions nebulized in the 
closed  chamber using ten  mice for each  dilution.  Forty-eight hours  after  challenge  three 
mice in each group were sacrificed and 10 per cent lung virus suspension prepared. The EIDs0 
of these suspensions were determined. The mice were observed for 14 days after challenge 
for death or survival. Those alive at  14 days were sacrificed and pulmonary lesions noted. 
The low challenge dose of virus was employed in order to avoid a  break-through of ho- 
mologous immunity and  thus to increase the  sensitivity of the cross-protection test.  This 
along with the above observation of lung virus titer at 48 hours, death or survival and pres- 
ence or absence of pulmonary lesions in surviving mice made it possible to detect differences 
in  degrees  of  cross-protection among  the  variants and  the  original PR8-S  virus. CLAYTON  G.  LOOSLI,  DOROTHY  ttAMP~,  AND  PAUL  GERBER  863 
In  Table  III  are  shown  the  results  of  cross-protection  tests  employing 
the fifth, sixth,  and seventh variants of the first series and  the PR8-S virus. 
In  all  three  experiments  all  control  mice  challenged  with  the  PR8-S  virus 
or a  variant  showed  comparable high  titers  in  the  lungs  at  48  hours  while 
mice  challenged  with  homologous  virus  showed  no  virus  at  this  time.  The 
Fd-vaccinated  mice  was  the  only  group  which  appeared  to  be  completely 
resistant  to  challenge  with  the  PR8-S  virus  since  none  died  and  no  virus 
TABLE  V 
Cross-Protection Tests with PR8-S and Cb and D/s Variants 
Experiment 
No. 
Challenge virus 
100 LADso 
PR8-S 
Cb 
PR8-S 
D/s 
Vaccine  group 
Control 
PR8-S 
Cb 
Control 
PR8-S 
Cb 
Control 
PR8-S 
D/s 
Control 
PR8-S 
D/s 
H.I. titer 
Dead  PR8-S  Variant  Total 
--  --  lO/lO 
640  10  0/i0 
320  480  0/10 
Results of challenge 
-  -  lO/lO 
64O  10  0/i0 
320  480  0/10 
--  --  10/10 
748  <16  0/10 
192  256  0/10 
--  --  lO/lO 
768  <  16  0/10 
192  256  0/10 
* Geometric mean antibody titer of five mice,  to 14 days 
hours after challenge. Homologous titers in bold type. 
Lesions  Lung titer 
Total  EIDi0 
10/10  10.0 
0/10  < 1.0 
0/10  2.3 
10/10  9.5 
5/10  6.5 
0/10  <1.0 
10/10  9.7 
0/10  < 1.0 
1/10  8.7 
10/10  9.0 
10/10  8.0 
0/10  <1.0 
after last dose. Log EIDl0 48 
could be detected in the lungs at 48 hours.  The mice vaccinated with Gf and 
Hg variants  and  challenged  with  PR8-S virus  showed moderately high lung 
virus  titers  but  two deaths  and  only one Ha-vaccinated mouse showed pul- 
monary  lesions.  On  the  other  hand  all  PR8-S-vaccinated  mice  challenged 
with  the  variants  showed  high  lung  virus  titers  at  48  hours.  Some in  each 
group died and many surviving mice showed pulmonary lesions. 
The differences in  the  cross-immunity tests  can be explained on the  basis 
of  the  relative  amounts  of  antibody  provoked  by  the  heterologous  virus. 
PR8-S produced little or no antibody to the variants while the variants, with 
the  exception  of  Gf,  provoked considerable  antibody  to  PR8-S.  The degree 
of cross-protection between PR8-S and the Gf variant was greater than would 
be expected on the basis of antibody titers in the mice. 864  ANTIGENIC  VARIANTS  OF IN~LU'ENZA  A  VIRUS.  V 
Cross-Protection  Tests  with  PR8-S  and  the  Variant  Viruses  of  the  Second 
Series.--Cross-H.I.  and  in  ovo  neutralization  and  antibody absorption  tests 
demonstrated a close antigenic  similarity between Cb and its D/s variant. 
In Table IV are shown the results of an experiment to compare the growth of Cb and 
D/s variants in the lungs of mice recovered from infections with PRS-S virus 6 weeks pre- 
viously. Homologous challenge showed the mice to be solidly immune to growth in the lungs 
at 48 hours even at the highest challenge dose while Cb and D/s grew about equally well 
in the PR8-S-recovered mice. In the mice challenged with 100 LDs0 doses the titer of D/s 
virus was significantly higher than the Cb virus titers. 
Cross-challenge tests with the Cb and its D/s variant and the PR8-S  virus are  shown 
TABLE  VI 
Cross-Protectlon Test with PR8-S Virus and Fd/s Variant 
Challenge  Vaccine  virus 100 
LAD~o  group 
PR8-S  Control 
PR8-S 
Fd/s 
Fd/s20  Control 
PR8-S 
Fd/s 
H. I. titer* 
~R8-S  Fd/s 
318~6 <8  96 
3~  <8 
96 
Results of challenge 
Lung titers:~  at time after challenge  I  Dead 
8 days  ---  24 hr.  48 hr.  3days4days  ....  6 d..ay  Total 
9.01  9.51 9.3j  d  lO/lO 
<1.01<1.01<1.01<1.0  <1.0<1.01  0/10 
5.3  5.7<1.0  2.7  <1.0<1.0  0/10 
8.5  7.31  8.5  8.13  d  <1.0  10/10 
4.0  s.7  7.0  s.7  s.7  2/lO 
<1.o  o/ o 
Lesions 
Total 
10/10 
o/lo 
1/10 
lO/lO 
8/lo 
o/lo 
* Titer at time of challenge 12 to 14 days after last vaccine dose. 
EIDso. 
in Table V. In these experiments all the unvaccinated control mice died and showed high 
lung virus titers at 48 hours.  Solid, homologous immunity was also present.  On  the other 
hand,  challenge of  Cb-  and  D/s-vaccinated  mice with  PR8-S  virus produced  lung virus 
titers of 2.3 and 3.7 respectively. PR8-S-vaccinated mice challenged with Cb and D/s vari- 
ants had virus titers of 6.5 and 8.0 respectively. These results also show the close  similarity 
of  these two variants as demonstrated previously by serological procedures.  Both reacted 
in  small amounts with  the  PRS-S  antiserum and  both produced  antibody  to  the  PR8-S 
virus almost or  as great as the respective homologous titers. 
In Table VI are given the results of a  cross-protection test with the second variant Fd/s 
of the second series and the PR8-S  virus. Larger numbers of mice were employed so that 
virus titers in the lungs at six intervals after challenge could be determined. It can be seen 
that the  two  antisera possessed only a  small amount of  H.I.  antibody for the respective 
heterologous virus. A  small amount of demonstrable antibody was present for the PRS-S 
virus in Fd/s antiserum while there was little or no antibody to the Fd/s virus in the PR8-S 
antiserum.  On  challenge with the  two  viruses all  the control mice  died  and  showed high 
virus titers in the lungs. Homologous challenge demonstrated solid immunity with no virus 
being demonstrated  at  any  of  the post-inoculation time  intervals.  Heterologous  infection 
was produced with both the PR8-S and Fd/s viruses. The infection was less severe in the 
Fd/s-vaccinated mice as indicated by the lower titer of virus in the lungs, no deaths, and CLAYTON  O.  LOOSLI~  DOROTHY  HAM-RE~ AND PAUL GERBER  865 
only one lung lesion in the ten surviving mice.  In the PR8-S  vaccinated mice challenged 
with the Fd/s virus the virus titer persisted in the lungs at moderately high titer for 6 days. 
Two of ten mice died and eight of ten showed lesions in the lungs. Again it is demonstrated 
that the extent of cross-protection between these viruses appears to be greater than is re- 
flected in  their serological relationships. 
The  results  of  cross-protection tests  with  the  third  and  fourth  variants 
(Gf/s and Hg/s)  the second  series and  the PRS-S virus are shown  in Table 
TABLE  VII 
Cross-Protection Tests with PR8-S Virus and Gf/s Variant; and with PR8-S and Hg/s 
Experiment 
No. 
Challenge virus 
100 LAD6o 
PRS-S 
Gf/s25 
PR8-S 
Hg/s30 
Vaccine group 
Control 
PR8-S 
Gf/s25 
Control 
PR8-S 
Gf/s25 
Control 
PR8-S 
Hg/s30 
Control 
PR8-S 
Hg/s30 
H.I. titer~ 
PRS-S  Variant 
450  <8 
<8  57 
450 
<8 
93 
<8 
93 
<8 
<8 
57 
<8 
27 
<8 
27 
Results of challenge 
Dead 
Total 
lo/lo 
o/lo 
O/lO 
lo/lo 
1/lO 
O/lO 
lO/lO 
o/lo 
o/lo 
lo/lo 
o/lo 
o/lo 
Lesions 
Total 
lO/lO 
o/lo 
o/lo 
lo/lo 
3/lo 
o/lo 
10/10 
o/lo 
0/lo 
I  lo/lo 
s/10 
o/lo 
Lung tater* 
EIDso 
9.6 
<1.0 
5.5 
I 
9.3 
6.5 
<1.0 
9.7 
<1.0 
7.0 
9.7 
7.6 
<1.0 
* 48 hours after challenge, pooled lungs three mice. 
"liter at time of challenge 12 to 14 days after last vaccine doses. 
VII. These variants produced no antibody to the PR8-S virus and the PR8-S 
antiserum contained no antibody to the variants.  The control mice in both 
experiments died and showed equally high virus titers in the lungs at 48 hours. 
Homologous challenge  showed solid immunity as indicated by no virus being 
demonstrated in the lungs  at 48 hours and no deaths or lesions in the mice. 
Heterologous challenge  showed  somewhat greater protection in  the  variant 
vaccinated mice infected with the PR8-S virus than occurred when the PR8-S- 
vaccinated mice were challenged  with  the  Gf/s and  Hg/s variants.  This is 
indicated  by  the  higher virus  titers  in  the  lungs  of the  PR8-S-vaccinated 
mice and noted with the presence of pulmonary lesions in the surviving ani- 
mals.  Again  the cross-protection tests reveal a  much closer relationship than 
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DISCUSSION 
Although the pathogenicity of the variants of the first  and second series  was 
similar to that of the original  PR8-S virus therc was a progressive loss  with 
each succeeding variant in the ability to provoke  antibodics. This loss of 
antigenicity may be the result  of the methods employcd in the development 
of the variant viruses.  As they were all  derived from their  passage in the lungs 
of homologously immune  mice, it might be expected that some of the more 
potent  antigens in the virus complex  would  be selectively neutralized or 
suppressed  by  their specific antibody  in the immune  environment.  Thus, 
the antigenic  complex of each succeeding variant would be expected to contain 
less  and less  potent antigens.  This appears to be the case  for  when the antigenic 
potency is compared in relation to the sequential deviation of the variants, 
a marked  and progressive decline in the ability of the variants to provoke 
an antibody response in mice and ferrets  can be seen. 
The  loss of antigenicity without  a significant decrease in pathogenicity 
among  thc variants of influenza PR8-S virus does not appear to correspond 
to P-Q variation as described by Van der Veen and Muldcr (3) and studied 
by Fiset and Depoux  (4).  The variants described here have been derived en- 
tirely by mouse passage. Q  strains  of influenza virus appear to arise  mainly 
among egg-adapted viruses,  after  passage of P strains  in eggs in the presence 
of homologous antiserum. Furthermore, Q strains  can be converted to P strains 
by mouse passage, but all antigenic variants described in this and preceding 
reports appear to bc stable  on passage in normal mice. 
In all cross-protection tcsts with PR8-S  parent  virus and  its variants, 
micc vaccinated with PR8-S virus were less  resistant to challenge with var- 
iant viruses than mice vaccinated with variant viruses and challenged with 
PR8-S. This reflected  the serological  relationships  shown between the variant 
viruses and PR8-S. All variants produced some antibody reacting  with PR8-S 
but the variant viruses  reacted slightly  or not at all  with the PR8-S antibody. 
Although Fd and Gf variants of the original  line,  and Fd/s and Gf/s variants 
of the Bar-S line  produced significantly  less  PR8-S antibody than other vari- 
ants of thesc two lines,  mice vaccinated with these variants were not signif- 
icantly less resistant to challenge with PR8-S  than mice vaccinated  with 
other variants. Although the serological  procedures showed marked antigenic 
differences between the PR8-S virus and its variants these differences were 
not as well demonstrated in the cross-protection tests. 
For instance, Fd and subsequent  variants of the original line, and Fd/s 
variant and subsequent variants of the Bar-S line  reacted little  if at all with 
PR8-S antiserum, but mice vaccinated with PR8-S nevertheless  showed some 
degree of resistance to challenge with these variants. Less than 50 per cent 
of these mice died. However,  lung lesions and titcr  of virus in lungs showcd 
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In recent years little attention has been paid to correlation of  serological 
differences with degree of cross-immunity in mice. In 1938 Francis and Magill (5) 
and Smith and Andrewes (6)  concluded that serological  differences among the 
type A  strains of that time could be correlated in a  general way with cross- 
immunity in mice. However, Francis and Magill (5)  pointed out that single 
doses  of  vaccine  often  failed  to  immunize  mice  to  homologous  challenge, 
while multiple doses of vaccine increased the degree of cross-protection among 
strains.  More  recently Francis  (7)  reported  that  mice  given  two  doses  of 
Keffer '47 strain produced little antibody to Rhodes '47 virus, yet were resistant 
to log 5.0 LDs0 intranasal doses of Rhodes virus.  Also,  Herzberg,  May,  and 
Beck (8)  recently reported that mice immunized with PR8-S  influenza virus 
which produced no antibody to FM1 virus, did not all die when challenged 
intranasally with FM1 strain. In their experiments most of the surviving mice 
showed lung lesions indicating a high degree of infection. It appears from these 
studies that use of death or survival alone in cross-protection tests with in- 
fluenza type A or A t strains is not sufficiently sensitive to correlate with even 
wide serological differences in the corresponding strains. The antigenic variants 
described in this report are more closely related to PR8-S than is FM1 virus. 
Therefore, it is hardly surprising that mice vaccinated with PR8-S and chal- 
lenged with the most serologically different variants did not all die. By using 
virus titer of the lungs at 48 hours, as well as deaths and lung lesions,  it is 
possible  to  demonstrate  lack  of  complete  reciprocal  immunity among  the 
variants  and  PR8-S  virus.  Thus,  the  results  of  cross-protection  tests  were 
in general agreement with serological  findings, that is PR8-S vaccine protected 
least  against challenge with  those variants  which  reacted least  with PR8-S 
antisera in the serological  tests. 
These  studies  demonstrate  clearly  the  antigenic  instability  of  influenza 
viruses when subjected to passage through a partially immune host. Whether 
the immune state of the human population has operated in a  similar fashion 
to  bring  about  the  progressive  antigenic  changes  in  the  group  A  influenza 
viruses since their first isolation in 1933 can only be surmised. These studies 
suggest that the alteration of antigenic components, in  such a  manner that 
older strains fail to provoke antibody against more recent  ones,  is  essential 
to the survival of influenza virus in man. In recent years, it has been noted 
that influenza viruses have also shown a decrease in their capacity to provoke 
homologous as well as heterologous antibody but no decline in their ability 
to infect man in widespread epidemics. These observations have their counter- 
part  in  our  studies of  the production of variant  influenza A  (PR8)  viruses 
following passage through immunized animals. 
SI/MMARY 
Two series  of variants of influenza PR8-S virus have been described. While 
all retain the same degree of pathogenicity for mice and fertile eggs, there was 868  ANTIGENIC VARIANTS  OF  INFLUENZA  A  VIRUS.  V 
a progressive loss in the ability of the variants to provoke antibody following 
vaccination or infection of mice and ferrets. The immunogenicity of the vari- 
ants  was,  therefore, less  than  that  of the  original  strain.  Although  little or 
no serological relationship could be demonstrated between some of the variants 
and the PR8-S virus a considerable degree of cross-immunity could be demon- 
strated  in  the  cross-protection tests  with  these viruses  if observations  were 
based solely on death or survival of the mice. By employing the occurrence 
of lesions in  the lung and  the titer of virus in the lung 48 hours after chal- 
lenge, the amount of cross-protection in mice could be related to the amount 
of  serological  cross-reaction.  In  general  mice  vaccinated  with  PR8-S  virus 
were less resistant to infection with the variant viruses than mice vaccinated 
with variants and challenged with the PR8-S parent virus. 
The role of the immune environment of the host in the production of the 
variant  influenza viruses  with  their  serological  differences,  decreasing  anti- 
genicity, and persisting pathogenicity as well as the epidemiological implica- 
tions of these findings with respect to epidemic influenza in man are discussed. 
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